tirzepatide vs semaglutide cual es mejor vs. Semaglutide: What You Should Know Tirzepatida vs Semaglutida ¿Cuáles son

STEP 1 (N = 1,961 adults with obesity, no diabetes): Semaglutide 2.4 mg weekly vs placebo 68-week treatment duration Mean weight loss: 14.9% of baseline body weight (semaglutide) vs 2.4% (placebo) 86% of semaglutide patients lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Published in New England Journal of Medicine, 2021 (Wilding et al.) STEP 2 (N = 1,210 adults with obesity and type 2 diabetes): Semaglutide 2.4 mg vs 1 mg vs placebo 68-week duration Mean weight loss: 9.6% (2.4 mg dose) vs 7.0% (1 mg dose) vs 3.4% (placebo) Diabetes patients lose less weight than non-diabetic patients on the same dose, likely due to baseline insulin resistance Published in Lancet, 2021 (Davies et al.) STEP 3 (N = 611, semaglutide plus intensive behavioral therapy): Mean weight loss: 16.0% at 68 weeks Adding structured diet and exercise counseling improved outcomes by approximately 1% absolute weight loss vs medication alone STEP 4 (withdrawal study, N = 803): Patients who achieved weight loss on semaglutide were randomized to continue semaglutide vs switch to placebo Patients who continued semaglutide lost an additional 7.9% of body weight over 48 weeks Patients switched to placebo regained 6.9% of body weight This demonstrates that semaglutide requires ongoing treatment

Additionally, Semaglutide has been approved for weight management in individuals with obesity or overweight conditions, affirming its role as a valuable tool in managing weight effectively

These compounds reduce central neuroinflammation by lowering interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-), and limiting oxidative stress ( On the other side, current trends in precision psychiatry aim to classify subpopulations of patients with inflammatory depression, characterized by elevated markers of inflammation, increased glucose and lipid levels, neurovegetative symptoms, anxiety or irritability, and suicidal ideation (Wessa et al., 2026)

A personal or family history of thyroid cancer, pancreatitis, or certain gastrointestinal conditions requires careful discussion before starting either medication

Notably, they acknowledged competitor Lilly by name in commentary and admitted Lillys weight-loss drug had overtaken Wegovy in US prescriptions earlier in the year